Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06465186 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Trial completed · Enrollment target: estimated 80 to confirmed 85 · Primary and study completion dates changed from estimate of Aug 6, 2026 to Aug 3, 2026 · 3 more Show 6 more changesShow less
    • Trial completed
    • Enrollment target: estimated 80 to confirmed 85
    • Primary and study completion dates changed from estimate of Aug 6, 2026 to Aug 3, 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Site details revised at 6 of 68 sites
  2. 2 versions Re-verified since Jan 30, 2026, no change to tracked fieldsv31-v32
  3. Site details revised at 1 of 68 sitesv30
  4. Primary and study completion dates: Sep 21, 2026 to Aug 6, 2026v29
  5. Trial status: Recruiting to Active, Not Recruiting Site details revised at 68 of 68 sitesv28 Show 1 more changeShow less
    • Site details revised at 68 of 68 sites
Show 26 earlier versionsHide 26 earlier versions
  1. Site details revised at 4 of 68 sitesv27
  2. Site details revised at 3 of 68 sitesv26
  3. Site details revised at 7 of 68 sitesv25
  4. Site details revised at 1 of 68 sitesv24
  5. Study sites: 67 to 68v23
  6. Study sites: 65 to 67v22
  7. Site details revised at 1 of 65 sitesv21
  8. Study sites: 64 to 65v20
  9. Study sites: 63 to 64v19
  10. Site contacts updated at 1 of 63 sitesv18
  11. Study sites: 62 to 63 Primary and study completion dates: May 15, 2026 to Sep 21, 2026v17 Show 1 more changeShow less
    • Primary and study completion dates: May 15, 2026 to Sep 21, 2026
  12. Site contacts updated at 1 of 62 sitesv16
  13. Site details revised at 23 of 62 sitesv15
  14. Study sites revised (62)v14 See this version in full on ClinicalTrials.gov ↗
  15. Study sites: 61 to 62v13
  16. Site contacts updated at 1 of 61 sitesv12
  17. Study sites: 59 to 61 Secondary endpoints revised (6)v11 Show 1 more changeShow less
    • Secondary endpoints revised (6)

    See this version in full on ClinicalTrials.gov ↗

  18. Study sites: 57 to 59v10
  19. Study sites: 46 to 57v9
  20. Re-verified, no change to tracked fieldsv8
  21. Study sites: 35 to 46v7
  22. Study sites: 21 to 35v6
  23. Study sites: 10 to 21v5
  24. Study sites: 3 to 10v4
  25. Re-verified, no change to tracked fieldsv3
  26. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3 · Start date changed from estimate of Jul 18, 2024 to Jul 12, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 3
    • Start date changed from estimate of Jul 18, 2024 to Jul 12, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
NASH / MASH
654 trials monitored
See 22 trials at risk
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it
Trial Details
NCT Number NCT06465186
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
Enrollment 85 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov